MeiraGTx Holdings PLC (MGTX)
MeiraGTx Holdings plc is a clinical-stage genetic medicines company listed on NASDAQ under the ticker MGTX. The company focuses on developing therapies for serious diseases, with programs spanning ocular disorders, neurodegenerative conditions, and xerostomia. Its pipeline includes candidates for inherited retinal diseases, large degenerative eye diseases, radiation-induced and Sjogren’s-related xerostomia, Parkinson’s disease, achromatopsia, Leber congenital amaurosis, and other genetic and neurological conditions. MeiraGTx also has preclinical programs in areas such as retinol dehydrogenase 12 mutation-associated retinal dystrophy, Bardet-Biedl syndrome, amyotrophic lateral sclerosis, Alzheimer’s disease, and neovascular age-related macular degeneration. In addition, the company develops a riboswitch platform for metabolic peptide delivery and cell therapies for oncology, autoimmune disease, and chronic pain. Founded in 2015 and based in New York, MeiraGTx collaborates with Johnson & Johnson Innovative Medicine and Hologen Limited on selected gene therapy programs.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MGTX
|
$12.55
|
-0.1% Downside
|
Fair
|
$28.38
|
125.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-9.6x
|
-20.0x
|
14.5x
|
1.131 B
|
1.176 B
|
7.2%
|
56.5%
|
-4.2
|
—
|
-2.9%
|
